{"id":"NCT04100018","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer","officialTitle":"A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-06","primaryCompletion":"2023-06-01","completion":"2024-06-25","firstPosted":"2019-09-23","resultsPosted":"2024-07-22","lastUpdate":"2025-06-12"},"enrollment":1030,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["OPDIVO,","BMS-936558-01"]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm A: Nivolumab + docetaxel + prednisone","type":"EXPERIMENTAL"},{"label":"Arm B: Placebo + docetaxel + prednisone","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.","primaryOutcome":{"measure":"Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)","timeFrame":"from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months)","effectByArm":[{"arm":"Nivolumab + Docetaxel + Prednisone","deltaMin":9.43,"sd":null},{"arm":"Placebo + Docetaxel + Prednisone","deltaMin":8.74,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5901"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":5},"locations":{"siteCount":293,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Hong Kong","Israel","Italy","Japan","Mexico","New Zealand","Poland","Puerto Rico","Romania","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":256,"n":510},"commonTop":["Alopecia","Diarrhoea","Anaemia","Fatigue","Nausea"]}}